Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade

被引：0
|
作者：
Wei, Spencer [1 ]
Levine, Jacob [2 ]
Cogdill, Alexandria [1 ]
Zhao, Yang [1 ]
Anang, Nana-Ama [1 ]
Andrews, Miles [1 ]
Sharma, Padmanee [1 ]
Wang, Jing [1 ]
Wargo, Jennifer [1 ]
Pe'er, Dana [2 ]
Allison, James [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Sloan Kettering Inst, New York, NY USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P379
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [22] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
    Celine Boutros
    Ahmad Tarhini
    Emilie Routier
    Olivier Lambotte
    Francois Leroy Ladurie
    Franck Carbonnel
    Hassane Izzeddine
    Aurelien Marabelle
    Stephane Champiat
    Armandine Berdelou
    Emilie Lanoy
    Matthieu Texier
    Cristina Libenciuc
    Alexander M. M. Eggermont
    Jean-Charles Soria
    Christine Mateus
    Caroline Robert
    Nature Reviews Clinical Oncology, 2016, 13 : 473 - 486
  • [23] Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models
    Genoud, Vassilis
    Marinari, Eliana
    Nikolaev, Sergey I.
    Castle, John C.
    Bukur, Valesca
    Dietrich, Pierre-Yves
    Okada, Hideho
    Walker, Paul R.
    ONCOIMMUNOLOGY, 2018, 7 (12):
  • [24] Colitis induced by immune checkpoint inhibitors: Anti-CTLA-4 antibodies and anti-PD-1/PDL-1 antibodies
    Vozy, A.
    Coutzac, C.
    ONCOLOGIE, 2016, 18 (9-10) : 501 - 508
  • [25] Anti-PD-1, Anti-PD-L1 and Anti-CTLA-4 checkpoint inhibitor treatment leads to different responses in syngeneic tumor models
    Jantscheff, Peter
    Schaefer-Obodozie, Cynthia
    Moor, Sandra
    Weber, Holger
    CANCER RESEARCH, 2016, 76
  • [26] CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
    Goltz, Diane
    Gevensleben, Heidrun
    Vogt, Timo J.
    Dietrich, Joern
    Golletz, Carsten
    Bootz, Friedrich
    Kristiansen, Glen
    Landsberg, Jennifer
    Dietrich, Dimo
    JCI INSIGHT, 2018, 3 (13):
  • [27] Tumor eradication in a murine model of glioma with vaccination and anti-CTLA-4 but not anti-PD-1
    Field, Cameron S.
    Hunn, Martin K.
    Ferguson, Peter M.
    Yagita, Hideo
    Hermans, Ian F.
    Ancelet, Lindsay R.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [28] Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Maecker, Holden
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [29] Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy response
    Uzelac, Matthew
    Li, Wei Tse
    Li, Yuxiang
    Ongkeko, Weg M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Late interferon-gamma blockade improves antitumor efficacy of anti-CTLA-4 and anti-PD-1 combination treatment
    Mok, Stephen
    Chin, Renee
    Allison, James P.
    CANCER RESEARCH, 2020, 80 (16)
12345